Panel Leans Toward Valsartan MDL, But Grapples With Scope
The Judicial Panel on Multidistrict Litigation indicated Thursday that it will centralize cases arising from recent recalls of the generic blood pressure drug Valsartan due to contamination by known carcinogens, but...To view the full article, register now.
Already a subscriber? Click here to view full article